BridgeBio Launches Awareness Campaign for ATTR-CM, Enlists Freeman, White
Event summary
- BridgeBio Pharma launched a national health education campaign, 'Don’t Pass On Your Heart Health,' to raise awareness of ATTR-CM.
- The campaign features actor Morgan Freeman and sports business executive Howard H. White, who shared personal experiences with delayed diagnosis.
- ATTR-CM is often misdiagnosed as other forms of heart failure or aging, particularly impacting women over 55 and Black communities.
- Attruby® (acoramidis), BridgeBio’s treatment for ATTR-CM, demonstrated a 50% reduction in cardiovascular-related hospitalizations in a Phase 3 study.
The big picture
BridgeBio’s campaign highlights the ongoing challenge of rare disease awareness and diagnosis, particularly in conditions like ATTR-CM where symptoms mimic more common ailments. The use of high-profile advocates underscores the growing recognition of patient advocacy's role in driving adoption of specialized therapies. This initiative also speaks to the broader trend of pharmaceutical companies investing in direct-to-consumer education to address diagnostic delays and improve patient outcomes.
What we're watching
- Adoption Rate
- The success of the campaign hinges on whether it leads to increased patient and physician awareness, ultimately driving earlier diagnosis and treatment with Attruby.
- Market Penetration
- Given the disproportionate impact on Black communities, BridgeBio’s ability to effectively reach and engage this demographic will be crucial for maximizing market penetration.
- Competitive Landscape
- The emergence of other ATTR-CM therapies will likely intensify competition, requiring BridgeBio to continually demonstrate Attruby’s value proposition and maintain market share.
Related topics